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The Rho GTPase guanine nucleotide exchange factor Ect2 is
genetically and biochemically linked to the PKC oncogene in
non-small cell lung cancer (NSCLC). Ect2 is overexpressed and
mislocalized to the cytoplasm of NSCLC cells where it binds the
oncogenic PKC-Par6 complex, leading to activation of theRac1
small GTPase. Here, we identify a previously uncharacterized
phosphorylation site on Ect2, threonine 328, that serves to reg-
ulate the oncogenic activity of Ect2 in NSCLC cells. PKC
directly phosphorylates Ect2 at Thr-328 in vitro, and RNAi-me-
diated knockdown of either PKC or Par6 leads to a decrease in
phospho-Thr-328 Ect2, indicating that PKC regulates Thr-328
Ect2 phosphorylation in NSCLC cells. Both wild-type Ect2 and
a phosphomimetic T328D Ect2 mutant bind the PKC-Par6
complex, activate Rac1, and restore transformed growth and
invasion when expressed in NSCLC cells made deficient in
endogenous Ect2 by RNAi-mediated knockdown. In contrast, a
phosphorylation-deficient T328A Ect2 mutant fails to bind the
PKC-Par6 complex, activate Rac1, or restore transformation.
Our data support a model in which PKC-mediated phosphory-
lation regulates Ect2 binding to the oncogenic PKC-Par6 com-
plex thereby activating Rac1 activity and driving transformed
growth and invasion.
Epithelial cell transforming sequence 2 (Ect2) is a guanine
nucleotide exchange factor (GEF)3 for Rho family small
GTPases (RhoA, Rac1, and Cdc42), and Ect2 function is essen-
tial in the regulation of cytokinesis (1–5). Ect2 is composed of a
C-terminal GEF catalytic domain and anN-terminal regulatory
domain that modulates the GEF activity and intracellular local-
ization of Ect2 (Fig. 1A) (2). In nontransformed cells, Ect2 is
localized almost exclusively to the interphase nucleus in a
hypophosphorylated state, where it is thought to be inactive.
During mitosis, Ect2 becomes hyperphosphorylated and is dis-
tributed throughout the cytoplasm, and during cytokinesis it is
localized to the mitotic spindle at the cleavage furrow where it
plays a critical role in furrow scission through regulation of
RhoA (3).
As suggested by its name, Ect2 has also been implicated in
cellular transformation (6–13). Ect2was originally identified by
expression library screening for transforming genes expressed
in human epithelial tumor cells (7). Subsequent analysis dem-
onstrated that the original transforming Ect2 clone was gener-
ated as an artifact of the DNA isolation and transfection proce-
dure and corresponded to an N-terminally truncated protein
that had lost the autoinhibitory BRCT domains as well as the
tandem nuclear localization signals (NLS) but retained the
C-terminal GEF catalytic domain (N-Ect2) (Fig. 1A). Interest-
ingly, ectopic expression of N-Ect2 but not full-length Ect2
caused transformation in mouse fibroblasts (7, 8). However,
introduction of missense mutations that disrupted NLS func-
tion causes both mislocalization to the cytoplasm and activa-
tion of full-length Ect2 transforming activity, suggesting that
mislocalization to the cytoplasm can promote Ect2 oncogenic
potential (8). Expression analysis demonstrates that full-length
Ect2 is overexpressed in several human tumor types, suggesting
a role for Ect2 in these tumors (9–11, 14). However, these stud-
ies also suggest that unique mechanisms operate to regulate
oncogenic Ect2 function in human cancer cells (15). We
recently demonstrated that Ect2 is a potential oncogene in non-
small cell lung cancer (NSCLC) (6). Specifically, we found that
Ect2 mRNA and protein is highly overexpressed in human
NSCLC cell lines and primaryNSCLC tumors and that the Ect2
gene ECT2 is a target for frequent tumor-specific gene amplifi-
cations as part of the chromosome 3q26 amplicon (6). In
NSCLC tumors and cell lines, Ect2 protein ismislocalized to the
cytoplasm where it binds to the oncogenic PKC-Par6 complex
(6). Functional analysis demonstrated that Ect2 regulates Rac1
activity downstream of the PKC-Par6 complex. Interestingly,
our analysis also demonstrated that the PKC-Par6 complex
regulates the cytoplasmic mislocalization of Ect2, that the
transforming activity of Ect2 requires its interaction with
PKC-Par6, and that the role of Ect2 in transformation is dis-
tinct from its role in cytokinesis (6).
In this study, we investigate the mechanism by which the
PKC-Par6 complex regulates Ect2 function in NSCLC cells.
We find that Ect2 isolated fromNSCLC cells is highly phosphor-
ylated at the novel and previously uncharacterized site Thr-328
within its hinge-like domain. We further show that PKC
directly phosphorylates Thr-328 in vitro and that PKC and
Par6 regulate Thr-328 phosphorylation in intact NSCLC cells.
* This work was supported, in whole or in part, by National Institutes of Health
Grants R01 CA081436-13 and R21 CA151250-01. This work was also sup-
ported by the V Foundation for Cancer Research (to A. P. F.).
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. 1 and 2.
1 Recipient of a National Institutes of Health research supplement to promote
diversity in health-related research from the NCI.
2 To whom correspondence should be addressed: Dept. of Cancer Biology,
Griffin Cancer Research Bldg., Rm. 211, 4500 San Pablo Rd., Jacksonville, FL
32224. Tel.: 904-953-6109; Fax: 904-953-0277; E-mail: fields.alan@mayo.
edu.
3 The abbreviations used are: GEF, guanine nucleotide exchange factor;
NSCLC, non-small cell lung cancer; NLS, nuclear localization signal; DH, Dbl
homology; MDCK, Madin-Darby canine kidney cell; KD, knockdown; NT,
nontarget.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 286, NO. 10, pp. 8149 –8157, March 11, 2011
© 2011 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
MARCH 11, 2011 • VOLUME 286 • NUMBER 10 JOURNAL OF BIOLOGICAL CHEMISTRY 8149
Functionally, we demonstrate that Thr-328 phosphorylation is
important for the oncogenic activity of Ect2. Our data indicate
that Thr-328 phosphorylation is important for the ability of
Ect2 to support transformation by facilitating Ect2 binding
to the PKC-Par6 complex. Taken together, our data suggest
amodel forEct2regulationinwhichPKCdirectlyphosphory-
lates Ect2, an event that favors its interaction with the PKC-
Par6 complex and facilitates its GEF activity toward Rac1, a
critical downstream effector of PKC-Par6-Ect2-dependent
transformation.
EXPERIMENTAL PROCEDURES
Antibody Reagents and Cell Lines—The following antibodies
were used in these studies: Ect2 and RhoA (Santa Cruz Biotech-
nology, Santa Cruz, CA); PKC, Cdc42, and Rac1 (BD Trans-
duction Laboratories, San Jose, CA); -actin, MEK1, and lamin
A/C (Cell Signaling, Danvers,MA); FLAG epitope (Sigma). The
S-peptide monoclonal antibody was a kind gift from Dr. S.
Kaufmann, Mayo Clinic. The A427, A549, H1703, and MDCK
cell lines were obtained from the American Type Culture Col-
lection (Manassas, VA) and maintained in low passage culture
as recommended by the supplier.
Mass Spectrometry Analysis of Ect2 Phosphorylation—Ect2
was immunoprecipitated from cytosolic extracts of H1703 cells
as described previously (6). Immunoprecipitated Ect2 was
resolved by SDS-PAGE, and the band corresponding to Ect2
was excised and submitted to the Mayo Clinic Cancer Center
Protein Chemistry and Proteomics Shared Resource for pro-
teolytic cleavage and phosphorylation site analysis by mass
spectrometry. The SDS-polyacrylamide gel bands were pre-
pared for mass spectrometry analysis using the following pro-
cedures. Silver-stained gel bands were destained with 15 mM
potassium ferricyanide and 50mM sodium thioisulfate in water
until clear and then rinsed with water several times to remove
all color (16). The bands were then reduced with 50 mM tris(2-
carboxyethyl)phosphine, 50 mM Tris, pH 8.1, at 55 °C for 40
min and alkylated with 40 mM iodoacetamide at room temper-
ature for 40 min in the dark. Proteins were digested in situwith
either 30 l (0.005 g/l) of trypsin (Promega Corp., Madison,
WI), chymotrypsin, or Lys-C (Roche Diagnostics) in 20 mM
Tris, pH 8.1, 0.0002% Zwittergent 3-16, at 37 °C for 4 h to over-
night, followed by peptide extraction with 20 l of 2% trifluo-
roacetic acid and then 60l of acetonitrile. The pooled extracts
were concentrated to less than 5 l on a SpeedVac spinning
concentrator (Savant Instruments, Holbrook, NY) and then
brought to 0.15% formic acid, 0.05% trifluoroacetic acid for pro-
tein identification by nano-flow liquid chromatography elec-
trospray tandem mass spectrometry (nanoLC-ESI-MS/MS)
using a ThermoFinnigan LTQ Orbitrap Hybrid Mass Spec-
trometer (ThermoElectron Bremen, Germany) coupled to an
Eksigent nanoLC-two-dimensional HPLC system (Eksigent,
Dublin, CA). The peptide digest was back-loaded onto a 250-nl
OPTI-PAK trap (Optimize Technologies, Oregon City, OR)
custom-packedwithMichromMagic C8 solid phase (Michrom
Bioresources, Auburn, CA). Chromatography was performed
using 0.2% formic acid in both the A solvent (98% water, 2%
acetonitrile) and B solvent (80% acetonitrile, 10% isopropyl
alcohol, 10% water), and running a 2% B to 50% B gradient over
60min at 325 nl/min through aMichromMagic C18 (75 m
200 mm) packed tip capillary column. The LTQOrbitrap mass
spectrometer experiment was set to perform an Fourier trans-
form full scan from 375 to 1600 m/z with resolution set at
60,000 (at 400m/z), followed by linear ion trapMS/MS scans on
the top five [M  2H]2 or [M  3H]3 ions. Dynamic exclu-
sion was set to one repeat of the same ion, which is then placed
on an exclusion list for 15 s. The lock-mass option was enabled
for the FT full scans using the ambient air polydimethylcyclosi-
loxane ion of m/z  445.120024 or a common phthalate ion
m/z  391.284286 for real time internal calibration (17). This
gave 2 ppm mass tolerances for precursor masses. The
MS/MS raw data were converted to DTA files using extract_
msn.exe from Bioworks 3.2 and correlated to theoretical frag-
mentation patterns of tryptic peptide sequences from the Swis-
sProt data base using both SEQUESTTM (ThermoElectron, San
Jose, CA) andMascotTM (Matrix Sciences London, UK) search
algorithms. All searches were conducted with fixed modifica-
tion of carbamidomethyl-cysteine and variable modifications
allowing for oxidation ofmethionines, formyl-Lys, phosphoryl-
ated Ser, Thr, and Tyr, along with loss or H3PO4 and protein
N-terminal acetylation. The search was restricted to full tryp-
sin, chymotrypsin, or Lys-C generated peptides as appropriate,
allowing for two missed cleavages, and was left open to all spe-
cies. Peptide mass search tolerances were set to 10 ppm, and
fragment mass tolerances were set to  0.8 daltons. All protein
identifications were considered when individual peptide scores
were above the 95% percentile for probability and rank number
one of all the hits for the respective MS/MS spectra. The iden-
tified phosphorylation site on phosphorylated peptides was
manually validated.
Lentiviral RNAi Constructs, Cell Transduction, and Immu-
noblot Analysis—Lentiviral RNAi against human Ect2, PKC,
and Par6 was obtained from the Sigma Mission short hairpin
RNA library, packaged into recombinant lentiviruses, and char-
acterized for target gene knockdown (KD) as described previ-
ously (18). A nontarget lentiviral RNAi (NT-RNAi) that does
not recognize any human genes was used as a negative control.
RNAi target sequences and characterization of the specificity of
RNAi reagents were published previously (6). Stably trans-
duced NSCLC cell populations were generated as described
previously (18). Ect2, PKC, and Par6 RNAi constructs were
analyzed for efficiency of target gene KDby quantitative PCR as
described previously (6). Cell lysates from NT, Ect2, and PKC
KD cells were prepared in RIPA buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS) supplemented with protease inhibitor
mixture (Roche Applied Science) and phosphatase inhibitor
mixture I and II (Sigma) and subjected to immunoblot analysis
as described previously (19).
Plasmids, Transfections, and Immunoprecipitations—The
cDNAof full-length humanRNAi-resistant Ect2 described pre-
viously (6) was cloned into the pTrAP plasmid vector that con-
tains an S-peptide tag, His tag, and streptavidin-binding tag (a
kind gift from Dr. S. Kaufmann, Mayo Clinic). Ect2 cDNA
sequences weremutagenized to encode alanine substitutions at
Thr-328, Thr-341, and Thr-412 to remove these phosphoryla-
tion sites; in addition, Thr-328 was mutagenized to encode an
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aspartic acid substitution tomimic phosphorylation at this site.
Ect2 RNAi cells were transfected with the empty pTrAP vector,
or ones encoding wild-type Ect2, or Ect2 phosphorylation
mutants using Lipofectamine 2000 (Invitrogen). For co-immu-
noprecipitation experiments, Ect2 RNAi cells were co-trans-
fected with FLAG-tagged human Par6 plus either S-peptide-
tagged Ect2 or empty vector. Cell lysates were subjected to
immunoprecipitation and immunoblot analysis as described
previously (6, 18).
Soft Agar Growth and Cellular Invasion Assay—Anchorage-
independent growth and invasion were assayed as described
previously (6, 18, 19). Matrigel-coated plates were obtained
from BD Biosciences. Experiments were independently con-
ducted in triplicate at least three times.
Rho GTPase Activity Assays—The level of activated Rac1-
GTP, Cdc42-GTP, and RhoA-GTP was determined by affinity
pulldown as described previously (6, 18, 20). Densitometry was
performed using Kodak Molecular imaging software (Car-
estream Molecular Imaging, New Haven, CT). Results were
normalized to total Rac1, Cdc42 or RhoA.
Phospho-specific Thr-328 Ect2 Antibody Production and
Validation—Rabbit polyclonal antibodies to phosphorylated
peptides corresponding to phosphorylated Thr-328 Ect2 were
generated by 21st Century Laboratories (Montgomery, TX).
Immunogenic phosphopeptides were as follows: Ac-321CYLY-
EKANpTPELKKSV335-amide and Ac-321YLYEKANpTPELK-
KSVC335-amide. Rabbits were injected subcutaneously with
the phosphopeptides conjugated to keyhole limpet hematoxy-
lin, and sera were collected and analyzed for antibody titer by
ELISA. The sera were immunodepleted of antibodies recogniz-
ing the unphosphorylated forms of the above peptides, and
phospho-specific antibodies were affinity-purified with the
corresponding antigen. To validate antibody specificity, the
purified peptides Ac-321YLYEKANpTPELKKSVC335-amide
and Ac-321CYLYEKANpTPELKKSV335-amide were conju-
gated to bovine serum albumin (BSA), and dilutions of the puri-
fied BSA conjugate were spotted onto nitrocellulose sheets and
subjected to immunoblot analysis. In addition, H1703 NSCLC
cells were transiently transfected with wild-type, T328A, or
T328D S-peptide-tagged Ect2 expression plasmids using Lipo-
fectamine 2000 in accordance with the manufacturer’s instruc-
tions. Lysates were subjected to immunoblot analysis as
described below. The antibody was further validated by in vitro
 phosphatase treatment. Briefly, wild-type S-peptide-tagged
Ect2 was expressed and immunoprecipitated from H1703
NSCLC cells. Immunoprecipitated Ect2 was incubated in the
presence or absence of 200 ng of  phosphatase in 1 phospha-
tase buffer for 30 min at 30 °C. Reactions were terminated by
the addition of SDS sample buffer and boiling for 5min, and the
samples were subjected to SDS-PAGE and immunoblot analy-
sis using affinity-purified phospho-Thr-328 Ect2 antibody or
total Ect2 antibody. In some experiments, total Ect2was immu-
noprecipitated from H1703 NT, PKC KD, and Par6 KD cells
and subjected to SDS-PAGE and immunoblot analysis using
affinity-purified phospho-Thr-328 Ect2 antibody or total Ect2
antibody as described above. Primary lung tumor and adjacent
matched normal lung tissues were obtained from surgical
resections of NSCLC cancer patients under advised consent.
Fresh tissues were homogenized and lysed in RIPA buffer sup-
plementedwith protease inhibitormixture (RocheApplied Sci-
ence), phosphatase inhibitor mixture I and II (Sigma). Total
Ect2 was immunoprecipitated from lysates and subjected to
SDS-PAGE and immunoblot analysis using affinity-purified
phospho-Thr-328 Ect2 antibody or total Ect2 antibody as
described above.
Subcellular Fractionation—Cells were fractionated using
NE-PER nuclear and cytoplasmic extraction reagents (Pierce).
Nuclear and cytoplasmic fractions were subjected to immu-
noblot analysis using antibodies to Thr(P)-328 Ect2, total
Ect2, lamin A/C, and MEK1 (all at 1:1000), and HRP-labeled
secondary antibodies and ECL detection as described previ-
ously (6).
In Vitro Kinase Assays—PKC in vitro kinase assays were per-
formed as described previously (21). Briefly, purified recombi-
nant bacterially expressed full-length human Ect2 was incu-
bated in the presence or absence of 100 ng of recombinant
human PKC (Millipore, Danvers, MA) in reaction buffer (20
mM Tris-HCl, pH 7.5, 10 mM CaCl2, 10 mM MgCl2, and 40
g/ml phosphatidic acid) supplemented with 200 M ATP for
30 min at 25 °C. Reactions were stopped by addition of 2
Laemmli buffer, and phosphorylation was determined by
immunoblot analysis for Thr(P)-328 Ect2 and total Ect2 as
described above.
RESULTS
Identification of a Novel Phosphorylation Site on Ect2 in
NSCLC Cells—We recently identified Ect2 as a potential onco-
protein in NSCLC (6). Ect2 protein is overexpressed in NSCLC
cell lines and primary NSCLC tumors and is mis-localized to
the cytoplasm in NSCLC cells where it binds to the oncogenic
PKC-Par6 complex (6). Through its interactionwith the PKC-
Par6 complex, Ect2 regulates the activity of Rac1, which in turn
is necessary for the transformed growth and invasion ofNSCLC
cells (6). Because Ect2 activity and intracellular localization
have been shown to be regulated by site-specific phosphoryla-
tion events (1, 3, 5), we assessed the phosphorylation status of
endogenous Ect2 co-immunoprecipitated with the PKC-Par6
complex from the cytoplasm of H1703 NSCLC cells (Fig. 1B).
Tryptic digestion and mass spectrometric (MS) analysis using
high performance liquid chromatography (HPLC) interfaced
to electrospray ionization on tandem mass spectrometers
(LCQ-XP or LTQ-FT, Thermo Electron) detected a single, pre-
viously uncharacterized phosphorylation site within the Ect2
protein, threonine 328 (Fig. 1A). SubsequentMS analyses using
a combination of trypsin, chymotrypsin, and Lys-C proteases
detected phospho-Thr-328 as the only phosphorylation site on
Ect2. This combination of proteases provided 90% coverage
of the coding sequence of Ect2, including essentially all pre-
dicted potential Ser/Thr phosphorylation sites as analyzed by
SiteScan (supplemental Fig. 1). MS analysis of tryptic digests of
Ect2 isolated from A549 and A427 NSCLC cells also identified
Thr-328 as the sole detected phosphorylation site, indicating
that Thr-328 phosphorylation is not restricted to H1703 cells.
These data indicate that Thr-328 is a major site of phosphory-
lation on Ect2 in human NSCLC cells, although we cannot
exclude the possibility that other phosphorylation sites on Ect2
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are also phosphorylated that were not detected in our analysis.
Interestingly, Thr-328 is positioned immediately N-terminal to
two consensus NLS previously implicated in the regulation of
Ect2 GEF activity and intracellular localization (1, 8).
Phosphorylation of Ect2 at Thr-328 Is Functionally Important
for Anchorage-independent Growth and Invasion of NSCLC
Cells—We previously demonstrated that Ect2 is functionally
important for anchorage-independent growth and invasion of
NSCLC cells in vitro (6). Therefore, we assessed whether phos-
phorylation at Thr-328 is important for the oncogenic activity
of Ect2 in NSCLC cells. Thr-328 on Ect2 was mutagenized to
alanine to produce an Ect2 mutant that is no longer capable of
being phosphorylated at this site (T328A) or to aspartic acid to
mimic Thr-328 phosphorylation (T328D). cDNA sequences
encoding these mutations were introduced into pTrAP-N1-
hEct2, a eukaryotic expression vector encoding an S-peptide
tag fused to the N terminus of human Ect2 encoded by a cDNA
sequence to which silent mutations had been made to render it
resistant to lentiviral RNAi-mediated Ect2KDas described pre-
viously (6). H1703 NSCLC cells were stably transfected with
empty control vector, wild-type (WT) Ect2, T328A-Ect2, or
T328D-Ect2 (6). Ect2 transfectants were then transduced with
recombinant lentivirus containing either a nontarget (NT) con-
trol or Ect2 RNAi construct, and stable populations of trans-
duced cells were isolated by puromycin selection as described
previously (6). Immunoblot analysis demonstrated the efficient
KDof endogenous Ect2 expression, and the stable expression of
exogenous WT and Ect2 phospho-mutants in Ect2 RNAi cells
to levels approaching those of endogenous Ect2 inNT cells (Fig.
2A). As expected, Ect2 KD cells expressing empty vector exhib-
ited impaired anchorage-independent growth and invasion
when compared with NT control cells (Fig. 2, B and C), consis-
tent with our published results (6). Interestingly, expression of
either exogenous WT Ect2 or the T328D-Ect2 phospho-mu-
tant significantly restored anchorage-independent growth and
invasion to Ect2 KD cells, whereas expression of the T328A-
Ect2mutant did not (Fig. 2,B andC). These results indicate that
phosphorylation of Ect2 at Thr-328 is functionally important
for both the anchorage-independent growth and invasion of
H1703 NSCLC cells.
The inability of theT328Amutant to support transformation
may result from this mutant possessing dominant-negative
properties. Therefore, we assessed anchorage-independent
growth and invasion in H1703 cells expressing vector control,
WTEct2, T328A-Ect2, or T328D-Ect2. Expression ofWTEct2,
phospho-deficient, or phospho-mimicmutants of Thr-328 had
no significant effect on the invasiveness or anchorage-indepen-
dent growth ofH1703 cells comparedwith cells expressing vec-
tor control (supplemental Fig. 2). Thus, the inability of the
T328A-Ect2 mutant to rescue Ect2 KD was not due to a domi-
nant-negative effect of this mutant.
Ect2 is phosphorylated in a cell cycle-dependent fashion.
Two major mitotic Ect2 phosphorylation sites for cyclin-de-
pendent kinase 1 (Cdk1) (Thr-341 and Thr-412) have been
identified within the central hinge region that are important in
regulating Ect2 localization andGEF activity during cytokinesis
(1, 4, 5). Therefore, we determined whether phosphorylation at
these sites was also important for the oncogenic activity of Ect2.
For this purpose, we assessed the effect of expressing WT and
Thr to Ala Ect2 mutants in Ect2 RNAi cells to restore transfor-
mation in NSCLC cells (Fig. 3A). Expression of either a T341A
or a T412A mutant of Ect2 in H1703 Ect2 RNAi cells restored
anchorage-independent growth and invasion to a level compa-
rable with that restored by WT Ect2, whereas the T328A Ect2
mutant failed to do so (Fig. 3, B andC). These data indicate that
phosphorylation of Ect2 at Thr-328 is required for the function
of Ect2 in transformation, whereas phosphorylation of Thr-341
or Thr-412 appears to be dispensable for this aspect of Ect2
function. Interestingly, expression of the T328A, T341A, and
T412A Ect2 mutants had no appreciable effect on the adherent
growth rate of H1703 cells and failed to induce accumulation of
multinucleated cells indicative of a cytokinesis defect (data not
FIGURE 1. Identification of a unique phosphorylation site on Ect2. A, schematic diagram showing the domain structure of Ect2 and the unique Thr-328
phosphorylation site detected in this study. BRCT, BRCA-like C-terminal domain; DH, Dbl homology RhoGEF catalytic domain. Shown are the full-length Ect2
protein and the original N-Ect2 transforming Ect2 clone (7). B, Ect2 is associated with the PKC-Par6 complex in NSCLC cells. Immunoprecipitation of
FLAG-tagged Par6 from cytoplasmic extracts of H1703 NSCLC cells co-precipitates PKC and Ect2. The identity of the bands on the silver-stained gel was
determined by mass spectrometry.
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shown). These data are consistent with our recent observation
that Ect2 KD in NSCLC cells does not induce a cytokinesis
defect and further confirm that the role of Ect2 in transforma-
tion is distinct from its role in cytokinesis (6). These results are
also consistentwith our previous observation thatNSCLCcells,
including H1703 cells, undergo cytokinesis in an Ect2-inde-
pendent fashion (6) and similar to what has been observed in
HT1080 fibrosarcoma cells (22).
Phosphorylation of Thr-328 Regulates Rac1 Activity in
NSCLC Cells—We recently demonstrated that Ect2 selec-
tively regulates Rac1, but not RhoA or Cdc42, activity in
NSCLC cells and that Rac1 is an important effector of Ect2-
mediated transformation in NSCLC (6). Therefore, we
assessed Rac1, RhoA, and Cdc42 activity in H1703 Ect2 KD
cells stably transfected with empty vector or WT, T328A,
and T328D Ect2 (Fig. 4A). As we observed previously (6),
H1703 Ect2 KD cells expressing an empty vector control
plasmid exhibited a statistically significant decrease in Rac1
activity compared with H1703 NT cells (Fig. 4B). Expression
of either WT or T328D Ect2 in Ect2 KD cells significantly
restores Rac1 activation, whereas the T328A mutant does
not. In contrast, no significant changes in Cdc42 or RhoA
activity were observed in these cells. These results are con-
sistent with a role for Thr-328 Ect2 phosphorylation in Ect2-
mediated activation of Rac1 in NSCLC cells.
FIGURE 2. Effect of Thr-328-Ect2 phospho-mutants on anchorage-inde-
pendent growth and invasion of NSCLC cells. A, immunoblot analysis of
H1703 NSCLC cells stably transduced with either nontarget (NT) or Ect2 RNAi
lentivirus and stably transfected with either empty vector (V) or one encoding
WT-Ect2 (WT), T328A-Ect2 (T328A), or T328D-Ect2 (T328D) mutants. B, effect of
WT and Thr-328-Ect2 mutants on anchorage-independent growth in soft
agar. Expression of either WT or T328D-Ect2 restores soft agar colony growth
to Ect2-RNAi cells, whereas expression of T328A-Ect2 does not. C, effect of WT
and Thr-328-Ect2 mutants on cellular invasion through Matrigel. Expression
of either WT or T328D-Ect2 restores cellular invasion to Ect2-RNAi cells,
whereas expression of T328A-Ect2 does not. Data in B and C represent the
mean  the S.E., n  4, and are presented as % NT control; * indicates signif-
icantly different from NT cells; ** indicates significantly different from Ect2
RNAi cells expressing control empty vector, p  0.05. Data shown are repre-
sentative of three independent experiments.
FIGURE 3. Mitotic Ect2 phosphorylation sites are not necessary for the
oncogenic activity of Ect2. A, immunoblot analysis demonstrating expres-
sion of S-tagged wild-type Ect2 (WT), T328A Ect2 (T328A), T341A Ect2 (T341A),
and T412A Ect2 (T412A) in Ect2 RNAi NSCLC cells. B, effect of WT, T328A,
T341A, and T412A Ect2 mutants on anchorage-independent growth in soft
agar. Only the T328A Ect2 mutant fails to restore soft agar colony growth to
Ect2-RNAi cells. C, effect of WT, T328A, T341A, and T412A Ect2 mutants on
cellular invasion through Matrigel. Only the T328A Ect2 mutant fails to restore
soft agar colony growth to Ect2-RNAi cells. Data in B and C represent the
mean  S.E., n  4, and are presented as % NT control; * indicates significantly
different from NT cells; ** indicates significantly different from Ect2 RNAi cells
expressing control empty vector; p  0.05. Data shown are representative of
three independent experiments.
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Thr-328 Is Highly Phosphorylated in NSCLC Cell Lines and
Primary NSCLC Tumors—To further characterize Thr-328
phosphorylation in Ect2-mediated NSCLC transformation,
we generated a rabbit polyclonal antibody that specifically rec-
ognizes Ect2 phosphorylated at Thr-328. Affinity-purified
Thr(P)-328 Ect2 antibodywas assessed for specificity by immu-
noblot analysis of purified phospho-Ect2 peptide conjugated to
BSA using the corresponding unphosphorylated Ect2 peptide
conjugated to BSA as a negative control (Fig. 5A). The Thr(P)-
328 Ect2 antibody specifically recognizes the phospho-Thr-328
peptide conjugate but not the unphosphorylated peptide con-
jugate (Fig. 5A). The Thr(P)-328 Ect2 antibody also recognizes
S-peptide-tagged Wt Ect2 but not S-peptide-tagged T328A or
T328DEct2mutants expressed in Ect2 RNAi cells (Fig. 5B).We
also characterized the specificity of the Thr(P)-328 Ect2 anti-
body by incubating total Ect2 immunoprecipitated fromH1703
cells in the presence or absence of  phosphatase. Immunoblot
analysis reveals that phosphatase treatment completely abol-
ishes the immunoreactivity of Thr(P)-328 Ect2 antibody for
Ect2 (Fig. 5C). Taken together, these results demonstrate that
our Thr(P)-328 Ect2 antibody is highly specific for Ect2 phos-
phorylated at Thr-328. Immunoblot analysis of Ect2 immu-
noprecipitated from nontransformed MDCK cells, and the
NSCLC cell lines H1703 and A549 for Thr(P)-328-Ect2 dem-
onstrate that both NSCLC cell lines express much higher levels
of Thr(P)-328-Ect2 than MDCK cells, which express relatively
little Thr(P)-328-Ect2 (Fig. 5D). We next assessed phospho-
Ect2 in a set of four primary NSCLC tumors andmatched adja-
cent lung tissues obtained from surgically resected NSCLC
tumors. Because Ect2 is overexpressed in NSCLC tumors, we
first conducted immunoblot analysis to determine the relative
abundance of total Ect2 in these samples (Fig. 5E, upper panel).
These results confirmed our previous finding (6) that NSCLC
tumors overexpress Ect2 compared with their matched normal
tissues. Densitometric analysis revealed a significant 2.3-fold
increase in total Ect2 in these tumors compared with matched
normal (n  4, p  0.05). To assess the relative abundance of
FIGURE 4. Effect of Thr-328 Ect2 phospho-mutants on Rac1, Cdc42, and
RhoA activity in NSCLC cells. A, Rac1-GTP (Active Rac1), RhoA-GTP (Active
RhoA), and Cdc42-GTP (Active Cdc42) and total Rac1, RhoA, and Cdc42 levels in
H1703 NSCLC cells expressing NT RNAi or cells expressing Ect2 RNAi and
either empty control vector (V), wild-type Ect2 (WT), T328A Ect2 (T328A), or
T328D Ect2 (T328D). B, quantitative analysis of Rac1-GTP levels. Data repre-
sent the mean  S.E. from three independent determinations. * indicates
significantly different from NT control; ** indicates significantly different from
empty vector; p  0.05. Data shown are representative of three independent
experiments.
FIGURE 5. Characterization of a phospho-specific Thr(P)-328 Ect2 anti-
body. A, dot blot analysis of a Thr(P)-328 Ect2 rabbit antibody. The indicated
amount of an Ect2 peptide-bovine serum albumin conjugate containing
either Thr-328 or phospho-Thr-328 (T328-BSA or Thr(P)-328-BSA) was slotted
onto a nitrocellulose filter and subjected to immunoblot analysis with
affinity-purified Thr(P)-328 Ect2 antibody as described under “Experimental
Procedures.” B, immunoblot analysis of Ect2 immunoprecipitates from Ect2
RNAi cells transfected with empty vector, WT, T328A, or T328D Ect2 mutants
with Thr(P)-328-Ect2 and pan-Ect2 antibodies. C,  phosphatase treatment
destroys the immunoreactivity of Thr(P)-328 Ect2 antibody against WT Ect2.
Total Ect2 immunoblot serves as a loading control in B and C. D, immunoblot
analysis for Thr(P)-328 Ect2 and total Ect2 from MDCK, H1703, and A549 cells.
Lysates from each cell line were subjected to immunoprecipitation with a
total Ect2 antibody followed by immunoblot analysis using Thr(P)-328 Ect2
and total Ect2 antibodies. H1703 and A549 cells express high levels of phos-
pho-Thr-328 Ect2 when compared with MDCK cells. E, total lysates (30 g of
protein) from NSCLC tumors (T) and matched normal tissue (N) were sub-
jected to immunoblot analysis to determine the relative levels of total Ect2
(upper panel). Ect2 was immunoprecipitated from extracts of primary NSCLC
tumors (T) and matched adjacent normal lung tissues (N) normalized to total
Ect2 content, and subjected to immunoblot analysis for Thr(P)-328 Ect2 and
total Ect2 (lower panel). In each case (P1–P4), Thr(P)-328-Ect2 levels are higher
in tumor tissue than in matched normal lung tissue.
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phospho-Thr-328-Ect2, we immunoprecipitated total Ect2
from an appropriate amount of lysate from each sample to yield
an equivalent amount of total Ect2. These immunoprecipitates
were then subjected to immunoblot analysis for phospho-Ect2
and total Ect2 (Fig. 5E, lower panel). Immunoblot analysis for
total Ect2 confirmed that equal amounts of total Ect2 were
present in each immunoprecipitate. Furthermore, immuno-
blotting for Thr(P)-328-Ect2 revealed that the level of Thr(P)-
328-Ect2was higher in the tumor sampleswhen comparedwith
matched normal lung tissue. Densitometric analysis for Thr(P)-
328-Ect2 revealed a significant 2.7-fold increase in Thr(P)-328-
Ect2 in tumors compared with matched normal tissue (n  4;
p  0.05). These results not only confirm that total Ect2 levels
are elevated in primary NSCLC tumors, but they also demon-
strate that Thr-328 Ect2 phosphorylation is increased in these
tumors (Fig. 5E).
We previously demonstrated that NSCLC cells exhibit mis-
localization of Ect2 to the cytoplasmwhere it binds to the onco-
genic PKC-Par6 complex (6). Therefore, we wished to assess
whether Thr(P)-328-Ect2 was preferentially localized to either
the nucleus or cytoplasm of NSCLC cells. For this purpose,
NSCLC cells were fractionated into nuclear and cytoplasmic
fractions as described previously (6), and each fractionwas sub-
jected to immunoblot analysis for Thr(P)-328-Ect2 and total
Ect2 (Fig. 6A). Whereas total Ect2 distributed roughly equally
between the nuclear and cytoplasmic fractions of NSCLC
cells, densitometry indicated that the Thr(P)-328-Ect2/total
Ect2 ratio was 2.3-fold higher (n  3; p  0.05) in the cyto-
plasmic fraction than in the nucleus (Fig. 6A). The purity of
our cellular fractions was confirmed by immunoblot analysis
for the nuclear A/C lamins and MEK1, markers of the
nucleus and cytoplasm, respectively. Thus, cytoplasmic Ect2
is highly phosphorylated at Thr-328 when compared with
nuclear Ect2 in NSCLC cells.
PKC Phosphorylates Ect2 at Thr-328 in Vitro and Regulates
Thr(P)-328 Ect2 Levels in NSCLC Cells—NSCLC cell transfor-
mation requires formation of the PKC-Par6 complex and
PKC kinase activity (18, 19). We therefore reasoned that sub-
strates important for PKC-mediated transformation might
associate with the PKC-Par6 complex.We recently identified
Ect2 as a component of the PKC-Par6 complex in NSCLC
cells and demonstrated that Ect2 becomes mislocalized to the
cytoplasm as a result of its interaction with the PKC-Par6
complex (6). Therefore, we assessed whether the phosphoryla-
tion status of Thr(P)-328-Ect2 is regulated by expression of the
PKC-Par6 complex. For this purpose, we assessed the level of
Thr(P)-328-Ect2 in cells made deficient in PKC or Par6 using
lentiviral RNAi as described previously (18). Both PKC- and
Par6-RNAi cells exhibited a decrease in Thr(P)-328-Ect2 when
compared with NT RNAi cells but showed no change in total
Ect2 expression (Fig. 6B), indicating that the PKC-Par6 com-
plex is involved in regulating Thr-328-Ect2 phosphorylation.
Given the preferential localization of Thr(P)-328-Ect2 to the
cytoplasm and the decrease in Thr(P)-328 Ect2 phosphoryla-
tion in PKC- and Par6-RNAi cells, we assessed whether Ect2
serves as a direct substrate for PKC. Analysis of Thr-328 using
the ScanSite phosphorylation site prediction program sug-
gested that Thr-328 might represent a PKC phosphorylation
site. To directly assess whether PKC is a Thr-328-Ect2 kinase,
we determined the ability of purified recombinant PKC to
phosphorylate recombinant bacterially expressed Ect2. When
Ect2 is incubated with PKC, we observe Thr(P)-328-Ect2
phosphorylation that is not observed in recombinant Ect2 in
the absence of PKC (Fig. 6C). Furthermore, the level of Thr(P)-
328-Ect2 is greatly increased in the presence of phosphatidic
acid, a known activator of atypical PKCs (23–25). These data
demonstrate that PKC directly phosphorylates Ect2 at Thr-
328 in vitro.
Phosphorylation of Ect2 at Thr-328 Regulates Ect2 Binding to
the PKC-Par6 Complex—To assess the role of Thr-328 phos-
phorylation in Ect2 binding to the PKC-Par6 complex, we
determined the ability of WT-Ect2, T328A-Ect2, and T328D-
Ect2 to bind to the PKC-Par6 complex. For this purpose, we
immunoprecipitated S-peptide-tagged Ect2mutants from Ect2
RNAi NSCLC cells (Fig. 6D). Both FLAG-tagged Par6 and
endogenous PKC were efficiently co-immunoprecipitated
withWT-Ect2 and theT328D-Ect2mutant, whereas little or no
Par6 or PKC co-immunoprecipitated with the T328A-Ect2
mutant. These data indicate that PKC-mediated Thr-328 Ect2
phosphorylation regulates the association of Ect2 with the
PKC-Par6 complex in NSCLC cells.
FIGURE 6. PKC directly phosphorylates Ect2 on Thr-328 and regulates
Ect2 binding to the PKC-Par6 complex. A, nuclear and cytoplasmic
extracts from H1703 cells were subjected to immunoprecipitation for total
Ect2 followed by immunoblot analysis for Thr(P)-328-Ect2 and total Ect2.
Immunoblot analysis of lamin A/C and MEK1 serve as markers of nucleus and
cytoplasm, respectively. B, RNAi-mediated knockdown of PKC and Par6 leads
to a reduction in cellular Thr(P)-328 Ect2 abundance. H1703 cells were trans-
duced with either NT, PKC, or Par6 RNAi as described previously (6). Lysates
were subjected to Ect2 immunoprecipitation (IP) followed by immunoblot
analysis for Thr(P)-328-Ect2 and total Ect2. C, PKC directly phosphorylates
Ect2 at Thr-328. Recombinant human PKC and recombinant human Ect2
were combined in kinase buffer in the presence or absence of phosphatidic
acid (PA) as described under “Experimental Procedures.” Samples were then
subjected to immunoblot analysis for Thr(P)-328-Ect2 and total Ect2. D, bind-
ing of WT Ect2 and Ect2 mutants to the PKC-Par6 complex. H1703 NSCLC cells
expressing FLAG-Par6 were transduced with either NT or Ect2 RNAi. Ect2
RNAi cells were then transfected with either empty vector (Vector), or S-pep-
tide-tagged WT Ect2, (WT), T328A Ect2 (T328A), or T328D Ect2 (T328D). Lysates
were subjected to immunoprecipitation with S-peptide antibody followed by
immunoblot analysis for Ect2, PKC, and FLAG-tagged Par6. WT and T328D
Ect2 efficiently co-immunoprecipitates PKC and Par6, whereas T328A Ect2
does not. Data shown are representative of three independent experiments.
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DISCUSSION
Ect2 was initially identified as a proto-oncogene capable of
transforming NIH/3T3 fibroblasts (7). However, the molecular
mechanism(s) by which the oncogenic function of Ect2 is reg-
ulated are not well understood. Analysis of the original onco-
genic Ect2 clone revealed that it encodes an N-terminally trun-
cated protein that retains the C-terminal RhoGEF catalytic
domain. This Ect2 truncationmutantmis-localized to the cyto-
plasm, possessed constitutive GEF activity, and could trans-
form fibroblasts in vitro (8). In contrast, full-length Ect2 local-
ized almost exclusively to the nucleus and was not capable of
transforming fibroblasts (8), consistent with the observation
that sequences within the N-terminal region of Ect2 serve to
regulate Ect2 localization and RhoGEF activity. Interestingly,
deletion of the C-terminal region of this truncated Ect2 signif-
icantly reduced Ect2 transforming activity (8, 13) and led to a
selective loss of GEF activity toward Rac1 (13). Thus, an Ect2
mutant consisting of the isolated DH/PH domains (Ect2-DH/
PH) was able to activate only RhoA in vitro and in vivo, whereas
an Ect2mutant consisting of theDH, PH, andC domains (Ect2-
DH/PH/C) activated RhoA, Rac1, and Cdc42 in vitro. Expres-
sion of the Ect2-DH/PHmutant enhances actin stress fiber for-
mation indicative of RhoAactivation,whereas expression of the
Ect2-DH/PH/Cmutant caused lamellipodia formation charac-
teristic of Rac1 activation (13). These data provided circum-
stantial evidence that Rac1 is a critical effector of Ect2-depen-
dent transformation and is consistent with our subsequent
findings in NSCLC (6). These data also indicate that the C
domain of Ect2 is important for conferring Rac1 GEF activity
upon Ect2.
These early results indicated that Ect2 is theoretically capa-
ble of causing cellular transformation and suggested a connec-
tion between cytoplasmic localization of Ect2, Rac1 GEF activ-
ity, and oncogenic potential. However, these studies did not
specifically address the role of Ect2 in human tumor cell trans-
formation or themechanisms underlying the cytoplasmic local-
ization of oncogenic Ect2. We recently demonstrated that Ect2
is genetically and biochemically linked to the PKC oncogene in
human NSCLC cells and primary NSCLC tumors (6). Specifi-
cally, we found that PKC and Ect2 are co-amplified and over-
expressed as part of the 3q26 amplicon in NSCLC tumors. Fur-
thermore, we demonstrated that Ect2 is mis-localized to the
cytoplasm of NSCLC cells as a consequence of its binding to
the oncogenic PKC-Par6 complex (6). Binding of Ect2 to the
PKC-Par6 complex is associatedwith activation of Rac1,which
is essential for the oncogenic activity of Ect2 (6). These results
provided a fundamental mechanistic understanding of how
Ect2 functions in transformation and themolecular basis for its
cytoplasmic mis-localization in tumor cells.
Our current results identify a molecular mechanism by
which the PKC-Par6 complex can activate the oncogenic
potential of Ect2. Here, we demonstrate that Ect2 isolated from
NSCLC cell lines and primary NSCLC tumors is highly phos-
phorylated at a previously uncharacterized site, Thr-328. Thr-
328 is located within the central hinge region of Ect2 between
the N-terminal regulatory domain and the C-terminal GEF
domain. Interestingly, earlier studies demonstrated that dele-
tion of this region results in an Ect2 mutant that exhibits trans-
forming activity, albeit weaker than an N-terminal truncation
mutant (8). Our data are consistent with a role for this region as
a negative regulator of Ect2 oncogenic activity. Our data also
demonstrate that phosphorylation at Thr-328 is important for
the oncogenic activity of Ect2 and that Thr-328 phosphoryla-
tion regulates the binding of Ect2 to the PKC-Par6 complex.
Our results are consistent with previous studies demonstrat-
ing a role for phosphorylation in the regulation of Ect2 function
(1, 3–5). Ect2 has been shown to be phosphorylated transiently
at two major sites within the hinge region during mitosis, Thr-
341 and Thr-412 (1, 3). These sites are phosphorylated by Cdk1
in a cell cycle-dependent manner and are important for regu-
lating Ect2 localization and activity during cytokinesis. Inter-
estingly, our results indicate that the Thr-341 and Thr-412
phosphorylation sites are not involved in the oncogenic activity
of Ect2 inNSCLCcells. These data support our previous finding
that the oncogenic activity of Ect2 is distinct from its role in
cytokinesis (6) and provide further evidence that the oncogenic
activity of Ect2 is unrelated to cytokinesis, at least in NSCLC
cells. Our data indicate that the three identified phosphoryla-
tion sites on Ect2, Thr-328, Thr-341, and Thr-412, play distinct
roles in Ect2 function. The fact that ectopic expression of ala-
nine mutants at each of these sites in NSCLC cells depleted of
endogenous Ect2 did not result in a cytokinesis defect indicates
that NSCLC cells have evolvedmechanisms for executing cyto-
kinesis that are either independent of Ect2 or that require
extremely low levels of Ect2 expression. Such an Ect2-inde-
pendent cytokinesis mechanism has also been described in
HT1080 fibrosarcoma cells (22).
Our current data provide novel insight into the biochemical
and functional relationship between PKC and Ect2. We previ-
ously demonstrated that these genes are genetically linked
through coordinate amplification and overexpression in
NSCLC tumors and biochemically linked through their associ-
ation in a cytoplasmic oncogenic complex with Par6 (6). Our
current data demonstrate that in addition to being a binding
partner for PKC, Ect2 also serves as a critical PKC substrate in
transformed cells and primary NSCLC tumors. Recombinant
PKC phosphorylates Ect2 at Thr-328 in vitro, and genetic
knockdown of PKC, or its binding partner Par6, leads to a
decrease in cellular Thr(P)-328 Ect2 phosphorylation. The
simplest interpretation of these data is that PKC directly phos-
phorylates Ect2 at Thr-328 in NSCLC cells, although the
involvement of an intervening kinase in vivo cannot be formally
ruled out. Our finding that Thr-328 is highly phosphorylated in
both NSCLC cell lines and primary tumors provides evidence
that PKC-mediated phosphorylation of Ect2 is important in
NSCLC tumor biology in vivo. Expression of Thr-328 Ect2
mutants indicates that Thr-328 phosphorylation regulates the
binding of Ect2 to the PKC-Par 6 complex and affects the GEF
activity of Ect2 for its critical downstream effector, Rac1. It
remains to be determined whether Thr-328 phosphorylation
functions primarily to activate the intrinsic GEF activity of Ect2
toward Rac1, induce, and/or stabilize the association of Ect2
with the PKC-Par6 complex which serves to bring Ect2 to its
substrate Rac1, or both. Our finding that a T328D-Ect2mutant
does not induce Rac1 activity or restore transformation in
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NSCLC cells lacking PKC (as a result of RNAi-mediated
knockdown) indicates that the interaction with the PKC-Par6
complex is a critical feature of the oncogenic function of Ect2.
Because Rac1 is a well characterized component of the PKC-
Par6 complex via interactions with the CRIB-like domain on
Par6 (26), we favor the interpretation that Thr-328 phosphory-
lation functions primarily to induce and/or stabilize the inter-
action of Ect2 with the PKC-Par6 complex where it can effi-
ciently activate Rac1. In conclusion, our present data identify a
novel PKC phosphorylation site on Ect2 that functions to reg-
ulate binding of Ect2 to the PKC-Par6 complex, thereby induc-
ing Rac1 activation and cellular transformation.
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